122 studies found for:    Open Studies | niaid
Show Display Options
Rank Status Study
1 Recruiting Interferon Responses in Eczema Herpeticum (ADEH)
Conditions: Atopic Dermatitis;   Eczema Herpeticum;   Herpes Simplex Infections;   Eczema Vaccinatum
Intervention:
2 Not yet recruiting Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults
Condition: HIV Infections
Intervention: Drug: Ruxolitinib
3 Not yet recruiting Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Conditions: Liver Transplant Recipient;   Living Donor (of the Respective Liver Transplant Recipient)
Interventions: Biological: darTregs;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Immunosuppression (IS) Withdrawal;   Procedure: Study Mandated Procedures
4 Not yet recruiting Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption
Condition: HIV Infections
Intervention: Biological: VRC01
5 Not yet recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
6 Not yet recruiting Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: PENNVAX®-GP HIV-1 DNA vaccine;   Biological: Interleukin-12 (IL-12) DNA adjuvant;   Biological: Placebo
7 Not yet recruiting Polyclonal Tregs for Lupus
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Discoid;   Lupus Erythematosus, Systemic
Intervention: Biological: Polyclonal Regulatory T Cells
8 Not yet recruiting Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Condition: HIV Infections
Interventions: Drug: MK-2048A IVR (Low Dose);   Drug: MK-2048A IVR (Original Dose)
9 Not yet recruiting Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo
10 Recruiting A Safety and Immune Response Study of 2 Experimental HIV Vaccines
Condition: HIV Infection
Interventions: Biological: ALVAC-HIV;   Biological: Bivalent Subtype C gp120/MF59®;   Biological: ALVAC-HIV (vCP2438) Placebo;   Biological: Bivalent gp120/MF59® Placebo
11 Recruiting Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults
Condition: Dengue
Interventions: Biological: rDEN1Δ30;   Biological: Placebo;   Biological: rDEN2Δ30-7169
12 Recruiting Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048
Condition: HIV Infections
Interventions: Device: Vicriviroc (MK-4176) Intravaginal Ring (IVR);   Device: MK-2048 IVR;   Device: MK-2048A IVR;   Device: Placebo IVR
13 Recruiting Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Conditions: HIV Infections;   Cardiovascular Diseases
Interventions: Drug: Pitavastatin;   Drug: Placebo
14 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
15 Recruiting Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Procedure: Blood Draw;   Procedure: CSF collection by lumbar puncture (Optional)
16 Recruiting A Clinical Trial of Fel d 1 Peptide Immunotherapy
Conditions: Cat Allergy;   Cat Hypersensitivity
Interventions: Drug: Cat-PAD;   Drug: Placebo for Cat-PAD
17 Recruiting Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA Nat-B env;   Biological: DNA CON-S env;   Biological: DNA Mosaic env;   Biological: MVA-CMDR;   Biological: Placebo for DNA Nat-B env;   Biological: Placebo for DNA CON-S env;   Biological: Placebo for DNA Mosaic env;   Biological: Placebo for MVA-CMDR
18 Recruiting Tocilizumab (TCZ) in New-onset Type 1 Diabetes
Conditions: Type 1 Diabetes Mellitus;   New-onset Type 1 Diabetes Mellitus;   T1DM;   T1D
Interventions: Drug: Tocilizumab (TCZ);   Drug: Placebo
19 Recruiting Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza
Conditions: Influenza A;   Influenza B
Interventions: Biological: Intravenous hyperimmune immunoglobulin (IVIG);   Biological: Placebo for IVIG
20 Recruiting Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 Anhui 2013/AA ca;   Biological: Inactivated subvirion H7N9 vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years